June 30, 2022.  St. Louis, MO.  Digital metabolic health startup Readout Health today announced that UCSF neuroendocrinologist Robert Lustig, MD and former Kaiser Permanente CMIO, Dr. John Mattison, MD have joined the Readout Health scientific advisory board to support clinical program development.

Dr. Lustig is Professor emeritus of Pediatrics in the Division of Endocrinology at UCSF, with over 40 years of clinical work and research focused on childhood obesity, diabetes, and systems issues that lead to metabolic disease. He is the author of five renowned books on metabolic health and the food industry, including the New York Times best-seller, Fat Chance: Beating the Odds against Sugar, Processed Food, Obesity, and Disease, as well as the recently published Metabolical: The Lure and the Lies of Processed Food, Nutrition, and Modern Medicine. In addition to his books, Dr. Lustig has published more than 200 scientific articles in peer-reviewed journals.

According to Dr. Lustig, “Personalized nutrition is just getting off the ground, but it’s doomed to fail without adequate metrics — thus, the push to develop and validate user-friendly methods to modulate and stick to your diet. I’m proud to help Readout Health implement Biosense, a user-friendly method to monitor your ketones so you can positively impact your health. And that’s just the beginning.”

Dr. John Mattison is currently an operating partner and CMIO of private equity firm Arsenal Capital Partners in New York after a long career as CMIO for the Southern California Region of Kaiser Permanente, one of the nation’s leading integrated healthcare institutions.

Dr. Mattison focuses on transforming care delivery with information technology, through convergence of exponential technologies and data liquidity. He led the design and implementation of the largest integrated electronic health record in the U.S., and leads various national programs including virtual care.

“Fat oxidation therapies are expanding into many therapeutic areas.  Adding strong advisors is critical to align our R&D resources to meet this expanding need for Biosense in the consumer, clinical, and research settings.  We are delighted to have both Drs.Lustig and Mattison support our mission in disease reversal,” said Jim Howard, CEO of Readout Health.

About Readout Health

Readout Health is a developing digital breath biomarker technologies for chronic disease prevention, management, and reversal.  Readout’s patented breath sampling technology isolates high concentration samples of breath compounds within handheld medical devices an supportive mobile apps.  Targeting behavior modification through precision biofeedback, Biosense®, a Class 1 medical device, was launched as an FDA Class 1 medical device after a successful 2019 clinical trial, enabling pharma and academic researchers and clinicians to monitor patient dosing of therapeutic ketosis (area-under-the-curve) in several therapeutic areas, including metabolic, neurocognitive, and oncology. For more information, visit https://mybiosense.com.